Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator
Jonathan Q. Tran; Jeffrey P. Hartung; Robert J. Peach; Marcus F. Boehm; Hugh Rosen; Heather Smith; Jennifer L. Brooks; Gregg A. Timony; Allan D. Olson; Sheila Gujrathi; Paul A. Frohna
Author Information: Receptos, a wholly owned subsidiary of Celgene Corporation
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.